Gamma frequency sensory stimulation in mild probable Alzheimer's dementia patients: Results of feasibility and pilot studies.
Diane Chan, Ho-Jun Suk, Brennan L Jackson...
https://pubmed.ncbi.nlm.nih.gov/36454969/Actively Recruiting
Led by Massachusetts Institute of Technology · Updated on 2026-03-27
150
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are studying the effects of non-invasive 40Hz sensory stimulation using light, sound, and tactile devices on brain activity in cognitively normal, healthy adults. This pilot study aims to explore whether such stimulation can alter brain oscillations and connectivity, improve neuropsychological measures, and affect blood biomarkers and the microbiome. The study is motivated by findings that disruptions in gamma-band brain activity are linked to Alzheimers disease and cognitive impairment, and current treatments have limited effectiveness. Participants receive stimulation from devices delivering light and sound at a 40Hz frequency, including a light and sound device with LEDs and speakers and a wrist- or hand-worn device that provides tactile vibrations. The devices are used during a one-day visit at MIT, where participants experience the stimulation in a controlled setting while watching videos for entertainment. During the visit, investigators evaluate the effects and safety of the GENUS stimulation using EEG, MEG, MRI scans, neuropsychological testing, and blood sampling in some participants. The primary outcome is to measure changes in brain oscillations after one year. This study involves adults aged 18 to 100 years, and participants are monitored for any biological effects and safety signals throughout the process.
CONDITIONS
Brain Effects of Gamma Frequency Sensory Stimulation (40Hz Light, Sound and Other Devices)
G
gamma wave
A
Ana Trisini Lipsanopoulos, BS
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Massachusetts Institute of Technology
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | GENUS 40 Hz light, sound (± tactile) device | Current non‑drug dementia care practices |
|---|---|---|
| What it is | A light and sound device (GENUS) delivering stimulation at 40 Hz (plus optional tactile component), positioned so that the user watches and listens during sessions in a sequential within‑participant design. | Standard practice includes non‑drug supportive care such as cognitive stimulation, exercise, structured activities, sensory engagement, reminiscence or music therapy. |
| Role in trial | Investigational device under evaluation for effects on brain oscillations in cognitively normal and Alzheimer’s participants. | Represents usual supportive care but was not tested in this trial. |
| Primary use | To provide 40 Hz sensory stimulation to modulate brain rhythms as a potential therapy. | To support cognition, mood, and daily functioning through structured non‑drug activities. |
| How it is given or performed | Device delivers light and sound at 40 Hz while participant sits viewing tablet or holds it, with optional tactile stimulation via wrist or handheld device. | Non‑drug care is delivered via activities like cognitive games, music, exercise or reminiscence guided by staff or caregivers. |
| Evidence status | Early-stage human trials suggest safety and feasibility, with preliminary signals of cognitive benefit and biomarker changes, but evidence remains limited. | Non‑pharmacological interventions are supported by guidelines but vary in evidence strength; approaches like cognitive stimulation and exercise have modest benefits. |
| Important limitations | Human evidence is limited to small pilot studies without randomized controls; long‑term benefits and safety remain to be proven. | Intervention formats and delivery vary widely; evidence strength and implementation consistency are limited. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 1 year
Participants use devices that deliver non-invasive 40Hz sensory stimulation through light, sound, or tactile methods to evaluate changes in brain activity and safety.
Regular visits to assess device use and outcomes may occur
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Diane Chan, Ho-Jun Suk, Brennan L Jackson...
https://pubmed.ncbi.nlm.nih.gov/36454969/Massachusetts Institute of Technology
Lead Sponsor